BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33007689)

  • 1. Cognitive enhancement, TAU phosphorylation reduction, and neuronal protection by the treatment of an LRRK2 inhibitor in a tauopathy mouse model.
    Castro-Sánchez S; Zaldivar-Diez J; Luengo E; López MG; Gil C; Martínez A; Lastres-Becker I
    Neurobiol Aging; 2020 Dec; 96():148-154. PubMed ID: 33007689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2 phosphorylates novel tau epitopes and promotes tauopathy.
    Bailey RM; Covy JP; Melrose HL; Rousseau L; Watkinson R; Knight J; Miles S; Farrer MJ; Dickson DW; Giasson BI; Lewis J
    Acta Neuropathol; 2013 Dec; 126(6):809-27. PubMed ID: 24113872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
    Nguyen APT; Daniel G; Valdés P; Islam MS; Schneider BL; Moore DJ
    Hum Mol Genet; 2018 Jan; 27(1):120-134. PubMed ID: 29088368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
    Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
    Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.
    Javidnia M; Hebron ML; Xin Y; Kinney NG; Moussa CE
    J Alzheimers Dis; 2017; 60(2):461-481. PubMed ID: 28869476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of phospho-specific Rab protein antibodies to monitor
    Lis P; Burel S; Steger M; Mann M; Brown F; Diez F; Tonelli F; Holton JL; Ho PW; Ho SL; Chou MY; Polinski NK; Martinez TN; Davies P; Alessi DR
    Biochem J; 2018 Jan; 475(1):1-22. PubMed ID: 29127256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
    Hamm M; Bailey R; Shaw G; Yen SH; Lewis J; Giasson BI
    J Neurosci Res; 2015 Oct; 93(10):1567-80. PubMed ID: 26123245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics.
    Bardai FH; Ordonez DG; Bailey RM; Hamm M; Lewis J; Feany MB
    PLoS Biol; 2018 Dec; 16(12):e2006265. PubMed ID: 30571694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing antibodies against LRRK2-targeted tau epitopes.
    Hamm M; Ladd TB; Levites Y; Golde TE; Giasson BI; Lewis J
    PLoS One; 2018; 13(9):e0204367. PubMed ID: 30261006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of chronic inhibition of the Parkinson's disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo.
    Kluss JH; Mazza MC; Li Y; Manzoni C; Lewis PA; Cookson MR; Mamais A
    Mol Neurodegener; 2021 Mar; 16(1):17. PubMed ID: 33741046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
    Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
    Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
    Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
    Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
    Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM
    Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues.
    Iannotta L; Biosa A; Kluss JH; Tombesi G; Kaganovich A; Cogo S; Plotegher N; Civiero L; Lobbestael E; Baekelandt V; Cookson MR; Greggio E
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain.
    Kelly K; Chang A; Hastings L; Abdelmotilib H; West AB
    Brain Res; 2021 May; 1759():147372. PubMed ID: 33600829
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Wauters F; Cornelissen T; Imberechts D; Martin S; Koentjoro B; Sue C; Vangheluwe P; Vandenberghe W
    Autophagy; 2020 Feb; 16(2):203-222. PubMed ID: 30945962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accurate MS-based Rab10 Phosphorylation Stoichiometry Determination as Readout for LRRK2 Activity in Parkinson's Disease.
    Karayel Ö; Tonelli F; Virreira Winter S; Geyer PE; Fan Y; Sammler EM; Alessi DR; Steger M; Mann M
    Mol Cell Proteomics; 2020 Sep; 19(9):1546-1560. PubMed ID: 32601174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration.
    Sanchez-Contreras M; Heckman MG; Tacik P; Diehl N; Brown PH; Soto-Ortolaza AI; Christopher EA; Walton RL; Ross OA; Golbe LI; Graff-Radford N; Wszolek ZK; Dickson DW; Rademakers R
    Mov Disord; 2017 Jan; 32(1):115-123. PubMed ID: 27709685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment.
    Guyot AC; Leuxe C; Disdier C; Oumata N; Costa N; Roux GL; Varela PF; Duchon A; Charbonnier JB; Herault Y; Pavoni S; Galons H; Andriambeloson E; Wagner S; Meijer L; Lund AK; Mabondzo A
    Sci Rep; 2020 Jan; 10(1):1143. PubMed ID: 31980673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.